Kornimate/medical-research-clean huggingface dataset:
mobile-phone-based psychoeducation for dementia caregivers in vietnam

Conditions: Depression, Anxiety; Stress

Summary: the goal of this study is to determine whether a mobile phone-based psychoeducational intervention can reduce stress among caregivers of individuals with dementia in vietnam. the primary research question is: does the intervention reduce levels of depression, anxiety, and stress among participants? the secondary research question is: does the intervention increase caregivers' knowledge about dementia, enhance social support, or reduce caregiver burden?

the study consists of two groups: an intervention group and a control group. participants in the intervention group will receive psychoeducational content through the zalo app on their mobile phones. weekly, they will be provided with a topic related to dementia care, such as daily caregiving, fall prevention, pressure injury prevention and care, self-care, and coping as a caregiver. levels of depression, anxiety, and stress will be assessed both before and after the intervention. in the control group, participants will continue receiving standard care.

Eligibility criteria:
inclusion criteria: * primary caregiver requirement: participants must have been the primary caregivers of poeple with dementia for at least the past 6 months and plan to continue in this role for the next 6 months of the intervention. patients with demeentia criteria: patients must have been diagnosed with dementia for at least 6 months and reside within the community. * language and education requirement: participants must be able to read and understand vietnamese (with at least a primary education level) and be willing to participate in the study. * smartphone requirement: participants must own a smartphone with the zalo app or be willing to install it (with a brief training session provided for new users). * age requirement: participants must be aged 18 years or older. exclusion criteria: * having any acute diseases or cognitive impairment (screening by mini-cog) or * having vision or hearing impairment

Keywords: dementia caregiver depression anxiety stress intervention psychoeducation mobile-phone
prevention of nausea and vomiting in patients after surgery

Conditions: Postoperative Nausea and Vomiting

Summary: postoperative nausea and vomiting (ponv) is a common problem after general anesthesia. the incidence can be as high as 80 percent in high-risk patients. investigators designed this randomized, double- blind, single-center study to compare the efficacy of the combination of dexamethasone with ondansetron and dexamethasone with aprepitant undergoing laparoscopic surgery. seventy american society of anesthesiologist (asa) physical class i-ii, age 18-60 years patients scheduled for laparoscopic surgery were included in this study. anesthesia was induced with propofol, fentanyl, and rocuronium, and maintained with sevoflurane in oxygen / air mixture in all patients. remifentanil was continuously infused during surgery. patients were randomly divided into two groups. patients in the dexamethasone and aprepitant group (group da, n=35) received 40 mg aprepitant orally 1 to 2 hours before induction of anesthesia and 2 ml saline intravenous (iv) within the last 30 minutes of surgery. patients in the dexamethasone and ondansetron group (group do, n=35) received an oral placebo identical to aprepitant 1 to 2 hours before induction of anesthesia and 4 mg ondansetron iv within the last 30 minutes of surgery. all patient received iv 8 mg dexamethasone after induction of anesthesia. ponv and postoperative opioid consumption were assessed for 24 hours postoperatively. the blindly evaluated primary outcome was complete response. the secondary outcomes were incidence of nausea, retching or vomiting, the need of rescue antiemetic and opioid consumption within 24 hours after surgery. statistical analyses were performed using mann-whitney u test, chi-square test, and fisher's exact test. p\<0.05 was considered statistically significant.investigators hypothesized that the antiemetic efficacy of the aprepitant and dexamethasone combination is superior compared with ondansetron and dexamethasone combination following the laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * 18 years to 60 years * asa (american society of anesthesiologist) physical status i or ii * patients undergoing laparoscopic gynecologic surgery or laparoscopic cholecystectomy exclusion criteria: * hypersensitivity or contraindication to the study medications, * antiemetic drug or steroid use within 24 hours before anesthesia, * history of diabetes mellitus, * history of motion sickness or postoperative nausea and vomiting, * pregnancy, * breast feeding

Keywords: dexamethasone, ondansetron aprepitant ponv laparoscopic surgery
efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation in egypt

Conditions: Hepatocellular Carcinoma (HCC); Living Donor Liver Transplantation

Summary: this study aimed to analyze the outcomes of loco-regional treatment prior living donor liver transplantation in patients with hcc.

50 patients received ldlt at ain shams centre for organ transplantation (ascot) over 1 year of whom data of 29 hcc patients were analyzed. twenty patients met the milan criteria (68.97%) \& 4 (13.8%) were beyond milan but met ucsf criteria and 5 were exceeding ucsf criteria (17.2%).all patients underwent preoperative lrts, the protocol of bridging/down staging, methods, duration of follow up, the number of the patients who were successfully down-staged before lt and their outcomes after lt were recorded.

Eligibility criteria:
inclusion criteria: 1. adult patients 18-65 years 2. patients transplanted for hcc within milan and ucsf criteria who underwent pre transplant bridge or down staging treatment for hcc exclusion criteria: 1. tumor progression on the waiting list 2. vascular invasion by imaging studies 3. extrahepatic or lymph node metastasis
the million anesthesia cases study (macs) - a cohort study of preoperative fasting and perioperative outcomes

Conditions: Anesthesia; Sedation; Monitored Anesthesia Care; Procedure; Surgery, Day; Surgery; Surgery Scheduled; Fasting Before Operation; Aspiration; Gastric Contents, Anesthesia

Summary: perioperative fasting has historically been viewed as a low-risk intervention. however, preliminary data indicate that perioperative loss of nutrition and fluids is likely harmful. this study intends to characterize perioperative fasting practices and their potential effects on clinical outcomes through possible effects on patient well-being (anxiety, hunger, thirst), physiology (hypovolemia, hypotension), perioperative aspiration, etc. we hypothesized that in addition to known adverse effects on patients' well-being, prolonged preoperative fasting adversely affects circulating blood volume-related (hypotension, decreased urine output etc.) and glucose metabolism-related (e.g., hypo/hyperglycemia) perioperative physiology. additional knowledge on the potential adverse effects of preoperative fasting will inform preoperative fasting policies and research interventions that are relevant to hundreds of millions of patients subjected to preoperative/preprocedural fasting worldwide each year.


Eligibility criteria:
inclusion criteria: * diagnostic or therapeutic procedure with anesthesia care (general anesthesia, regional anesthesia, sedation, or a combination of the above) exclusion criteria: * not receiving anesthesia care * lack of medical record data in epic electronic medical record system

Keywords: preoperative fasting perioperative pulmonary aspiration perioperative complications postoperative nausea and vomiting perioperative hypoglycemia perioperative hyperglycemia perioperative hypotension myocardial injury after noncardiac surgery perioperative acute kidney injury clear liquid fasting
assessment of postoperative lymphopenia as risk factor for postoperative infections

Conditions: Cancer of the Digestive System; Thoracic Diseases

Summary: postoperative infections are one of the most common complications in thoracic and digestive cancer surgery. former studies have demonstrated that inflammatory response is altered during peri-operative period causing lymphopenia. it has been suggested that lymphopenia may contribute to postoperative infection. to date, no one has proved it in a multivariate analysis. the aim of this study is to determine if lymphopenia is associated with postoperative infections in thoracic and digestive cancer surgery.

postoperative infections are one of the most common complications in thoracic and digestive cancer surgery. former studies have demonstrated that inflammatory response is altered during peri-operative period causing lymphopenia. it has been suggested that lymphopenia may contribute to postoperative infection. to date, no one has proved it in a multivariate analysis. the aim of this study is to determine if lymphopenia is associated with postoperative infections in thoracic and digestive cancer surgery. it is a multicenter french cohort study. lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery before surgery (day-0) as well 1, 3, 5 and 8 days after surgery. anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. clinical and biological signs of infection are collected.

Eligibility criteria:
inclusion criteria: * patient undergoing digestive or thoracic cancer surgery under general anesthesia. exclusion criteria: * pregnant women, * malignant blood disease, * allograft patient, * preoperative sepsis or preoperative systemic inflammatory response syndrome.

Keywords: lymphopenia postoperative infection thoracic cancer surgery digestive cancer surgery
continuous glucose monitoring system use in pediatric patients with diabetes

Conditions: Diabetes Mellitus

Summary: to verify and evaluate the efficacy and safety of i3 cgm system manufactured by changsha sinocare inc. for continuous or regular monitoring of interstitial fluid glucose level in pediatric patients with diabetes.

this clinical investigation is of a multi-center and self-controlled design. this clinical investigation is planned to be conducted in 3 study sites, with a total of 78 subjects to be enrolled, of which no fewer than 15 cases are aged 2-5 years old, and no fewer than 60 cases are aged 6-17 years old. this clinical investigation is to verify the safety and efficacy of the investigational device. referring to the number of pediatric patients with diabetes in the 3 study sites, it is expected that about 20 subjects will be enrolled in each site every month, and it will take about 2 months to close the site. this clinical investigation is expected to be completed in about 6 months from the first participant recruited. the real-time glucose values measured by cgm system on the left and right abdomen are compared with the venous blood glucose value (ekf value) measured by ekf analyzer, respectively, and the consistency rate is analyzed.

Eligibility criteria:
inclusion criteria: * aged 2 (inclusive) - 18 years (exclusive); * clinically diagnosed with diabetes; * being willing to wear the device continuously for 15 days and conduct blood collection for blood glucose testing in accordance with the requirements of this protocol; * body weight not less than 10.0 kg; * consent to participate in this clinical investigation, and sign the informed consent form (icf). exclusion criteria: * need to undergo magnetic resonance imaging (mri) during the clinical investigation; * diffuse subcutaneous nodules; * acute complications of diabetes; * abnormal coagulation function (coagulation cannot be too quick or too slow); the criteria for judging abnormalities are: the activated partial thromboplastin time (aptt) is higher than 1.5 times the upper limit of normal value or lower than the lower limit of normal value; or the prothrombin time (pt) is higher than 1.5 times the upper limit of normal value or lower than the lower limit of normal value * participation in other clinical investigations within the past 1 month; * where the investigator does not consider the patient suitable for enrollment.
frailty, anesthesia and complications.

Conditions: Frail Elderly Syndrome; Anesthesia Complication; Complication of Surgical Procedure; Postoperative Delirium; Physical Disability

Summary: objectives: to assess the prevalence of frailty in patients older than 70 y/o in nephrourologic surgery. to study if preoperative frailty is an independent predictor of immediate postoperative complications, after 30 days, 6 months and 1 year of follow-up. to detect if there are other independent risk factors for complications.

objectives: to assess the prevalence of frailty in patients older than 70 y/o in nephrourologic surgery. to study if preoperative frailty is an independent predictor of immediate postoperative complications, after 30 days, 6 months and 1 year of follow-up. to detect if there are other independent risk factors for complications. methods: prospective cohort study performed at fundació puigvert. enrollment of 850 patients ≥70 y/o who undergo scheduled nephrourologic surgery. in the preoperative visit frailty is going to be evaluated using the short physical performance battery (sppb), the canadian frailty scale, the mini-cog test (memory an executive functions), the pfeiffer test (cognitive global screening), an involuntary loss of more than 4.5kg or 5% of weight in the previous year and physical activity using the metabolic equivalents of task (met). we will analyse the relation among frailty, medical, surgical postoperative complications and mortality at 30 days, 6 months and one year after the surgery. the results will be adjusted by the possible confounding and interaction variables using a multivariate logistic regression model. the confounding /interaction variables will include demographic data, clinical and lab data and events arisen during the follow-up period.

Eligibility criteria:
inclusion criteria * patients who participate voluntarily * signed informed consent * 70+ years old * scheduled urological surgery with general or regional anesthesia and length of stay in hospital over 24 hours. * patients with preserved domiciliary deambulation without aid of another person. (walking sticks, or walkers are accepted) exclusion criteria: * no signing of the informed consent * surgery performed with local anesthetics * day surgery, extracorporeal wave lithotripsy or endourological catheterism * advanced diagnosed dementia * patients with chronic advanced disease or terminal oncological disease

Keywords: frailty anesthesia complications
drug-drug interaction study to evaluate the effect of isis 681257 on clopidogrel

Conditions: Elevated Lipoprotein(a); Cardiovascular Diseases

Summary: this is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of isis 681257 on the pharmacokinetics of multiple doses of clopidogrel


Eligibility criteria:
inclusion criteria: * motivated and available for duration of study and willing to adhere to protocol * males who are unable to procreate or agree to contraception throughout study * females who are postmenopausal or surgically sterile * bmi between 18.5 and 30 kg/m2 * weighing greater than or equal to 50kg * normal lab results * no known diseases or significant findings on physical exam exclusion criteria: * females of childbearing potential * reactions/infection at injection site * hypersensitivity to any drugs or similar drugs to those used in the study * conditions or disease that may interfere with study drug * any significant diseases * known history or familial history of bleeding disorders * drug dependency or abuse * illness within 28 days * previous exposure to other investigational drug within 28 days * blood donations within 28 days
intraosseous vs. intravenous vancomycin administration in total ankle arthroplasty

Conditions: Infections; Ankle Arthritis

Summary: the purpose of this study is to compare two different antibiotic regimens and techniques during total ankle arthroplasty (taa). primary objective: comparable levels of vancomycin will be found in bone, soft tissue, and systemic samples between patient groups. secondary objective: compare 30 day and 90 day post-operative complication rates (infection) between the control (standard iv administration of vancomycin) vs the interventional group (intraosseous administration of vancomycin). the investigators hypothesize that there will be no difference in complication (infection) rates between groups.


Eligibility criteria:
inclusion criteria * patient is undergoing total ankle arthroplasty. * patient is able to give informed consent to participate in the study. lar consents will not be utilized for this study * age range \>18 exclusion criteria * previous lower extremity surgery that in the opinion of the principal investigator or qualified research personnel precludes the participant from safely participating on the study. * bmi \> 40. * contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc). * inability to administer the io infusion. * patient refusal to participate. * uncontrolled diabetes mellitus type 1 or 2, defined as hemoglobin a1c \>7.5. * immunocompromised or immunosuppressed patients (hiv, hep c, end stage renal disease, dialysis, transplant, chemo/radiation treatment in last 6 months, medications). * vulnerable populations
optimal doses for drug provocation tests to beta-lactams

Conditions: Drug Hypersensitivity

Summary: drug provocation tests (dpt) are widely in case of suspicion of drug hypersensitivity (and in the absence of contraindications), but there are no standardized protocols and most groups use hypothesis (clinically-driven) protocols. investigators used 20 year experience in drug hypersensitivity to analyse retrospectively 171 patients (accounting for 182 positive dpt to beta-lactams). using survival analysis, they identified optimal doses to include in a data-driven protocol. this data-driven protocol will be applied to new prospective patients, to test its safety and benefits (gain in time, hospital and patient benefits).


Eligibility criteria:
inclusion criteria: * patients with positive drug provocation test (dpt) to beta-lactams exclusion criteria: * contra-indications to dpt * refusal of participation * vulnerable patients according to french regulation

Keywords: betalactams drug hypersensitivity drug provocation test reactive dose
humoral and t-cell responses to covid-19 vaccination in multiple sclerosis patients treated with ocrelizumab treated with ocrelizumab or natalizumab

Conditions: Multiple Sclerosis; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Pathologic Processes

Summary: the primary goal of this study is to provide additional data regarding b and t-cell mediated responses to covid-19 vaccines in ms patients treated with ocr and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. b-cell mediated humoral responses and adaptive t-cell mediated cellular responses were measured in patients treated with ocr who received any of the available sars-cov-2 vaccines, 3-4 weeks after completion of vaccination.

the purpose of this study is to see if patients on ocrelizumab (ocrevus) produce a humoral and t-cell response to the coronavirus vaccine. ocrelizumab depletes b-lymphocytes and has the potential to reduce the effectiveness of vaccines. the impact of ocrelizumab treatment on coronavirus vaccines is unknown. natalizumab (tysabri) likely has a minimal impact the efficacy of vaccines. in this study the investigators will take blood samples in patients being treated with either ocrelizumab or natalizumab before and after vaccination with an fda-authorized coronavirus (covid-19) vaccine and compare the antibody response in both groups.

Eligibility criteria:
inclusion criteria * age 18-55 * diagnosis of multiple sclerosis (as per the revised 2017 criteria) * edss score of 0-5.5 inclusive * has initiated ocrelizumab or natalizumab at least 6 months prior to study enrollment * for women of childbearing potential: agreement to remain abstinent or to use a highly effective (99% efficacy or greater) contraceptive method * individual must be able to provide consent, read/write/comprehend english language or must be able to provide a consistent translator exclusion criteria * previous infection with covid-19, confirmed by fda approved testing * cognitive impairment limiting the ability to consent or complete study procedures * currently pregnant, planning to become pregnant during the study period, or currently breastfeeding * any prior use of immunosuppressive or chemotherapy treatment (including, but not limited to, cladribine, alemtuzumab, mycophenolate mofetil, cyclophosphamide, methotrexate, azathioprine) * prior treatment with a b-cell depleting therapy other than ocrelizumab within 12 months of first on-study infusion excluding standard ocrelizumab pre-treatment therapy * use of systemic corticosteroid therapy within 12 weeks of screening (excluding corticosteroid treatment given concurrently with ocrelizumab) * history of allergic reactions to vaccines

Keywords: covid-19 natalizumab ocrelizumab ocrevus tysabri antibody coronavirus vaccine
ai derived plaque quantification: ccta and ai-qcpa for determining effective cad management

Conditions: Coronary Artery Disease

Summary: the objective of heartflow's decide registry is to collect observational data about the management of patients before and after heartflow artificial intelligence-quantitative coronary plaque analysis (ai-qcpa).

the decide registry is a post-market, multi-center, data collection study assessing the change in management of clinically stable patients who undergo ccta with plaque detected. data will be retrospectively collected following the ccta, and analyses will be completed 90 days, 180 days, and 1 year after ccta. data may be retrospectively collected annually up to 5 years.

Eligibility criteria:
inclusion criteria (all must be present) : 1. groups 1, 2,4,5 and 6: ccta and plaque detected 2. group 3: any patient with a stress test (stress echocardiogram or nuclear imaging including spect or pet) and no ccta within the 90 days prior to site activation 3. groups 1,2,3 and 4: clinically stable, symptomatic 4. group 6: clinically stable without symptoms suggestive of cad at the time of the ccta exclusion criteria (all must be absent) : 1. ed presentation (at the time of the ccta or stress test) 2. groups 1,2,3,4, and 6: previous history of cad (prior to the ccta or stress test with history of revascularization) 3. group 5: prior history of pci in multiple vessel territories, pci in the left main, cabg, and/or any other conditions or limitations which would prevent successful ccta processing by heartflow 4. acute chest pain (in patients who have not been ruled out for acs) 5. previously evaluated with and/or in a study which includes ai-qcpa

Keywords: cad ai-qcpa